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Abstract: Tumor angiogenesis has been identified to play a critical role in tumor growth 
and tumor progression, and is regulated by a balance of angiogenic and anti-angiogenic 
cytokines.  Among  them  VEGF  (vascular  endothelial  growth  factor)  and  its  signaling 
through its receptors are of crucial relevance. Inhibition of VEGF signaling by monoclonal 
antibodies or small molecules (kinase inhibitors) has already been successfully established 
for the treatment of different cancer entities and multiple new drugs are being tested in 
clinical trials. However not all patients are likely to respond to these therapies, but to date 
there  are  no  reliable  biomarkers  available  to  predict  therapy  response.  Many  studies 
integrated biomarker programs in their study protocols, thus several potential biomarkers 
have  been  identified  which  are  currently  under  clinical  investigation  in  prospective 
randomized studies. This review intends to give an overview of the described potential 
biomarkers  as  well  as  different  imaging  techniques  such  as  ultrasound  and  magnetic 
resonance  imaging  that  can  indicate  benefit,  resistance  and  toxicity  to  
anti-angiogenic therapies. 
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1. Introduction 
Tumor growth is crucially dependent on the development of new blood vessels, a process called 
angiogenesis. Since several years, tumor angiogenesis has been identified to play a critical role in 
tumor growth and tumor progression [1]. In adults, physiological angiogenesis is limited to a small 
number  of  specific  processes,  such  as  wound  healing,  tissue  repair  and  the  female  reproductive  
cycle [2]. Pioneered by the work of Judah Folkman, it was recognized that angiogenesis plays an 
important  role  in  tumor  development,  progression,  and  metastasis  in  solid  tumors  [1]  but  also 
hematological malignancies [3–5].  
Tumors  require  nutrients  and  oxygen  in  order  to  grow,  and  new  blood  vessels,  formed  by  the 
process  of  angiogenesis,  provide  these  substrates.  Tumor  blood  vessels  are  generated  by  various 
mechanisms, such as cooption of the existing vascular network, expansion of the host vascular network 
by budding of endothelial sprouts (sprouting angiogenesis), remodeling and expansion of vessels by 
the  insertion  of  interstitial  tissue  columns  into  the  lumen  of  pre-existing  vessels  (intussusceptive 
angiogenesis)  and  homing  of  endothelial  cell  precursors  (EPC;  CEP)  from  the  bone  marrow  or 
peripheral blood into the endothelial lining of neovessels (vasculogenesis) [6]. Bone marrow derived 
progenitor cells contribute significantly to neovascularization in a variety of tumors [7,8]. 
The key mediator of angiogenesis is the vascular endothelial growth factor (VEGF). Therefore, 
VEGF and its receptors are interesting targets for anticancer therapies [9]. VEGF signaling inhibition 
has been shown to result in significant tumor growth delay in a wide range of animal models [10]. In 
the case of VEGF even a single VEGF allele knock-out led to embryonic lethality in mice [11]. The 
clinical benefit of this approach has also been confirmed and concentrated efforts in recent years have 
resulted in a number of novel anti-angiogenic agents [12]. The humanized monoclonal anti-VEGF 
antibody bevacizumab is the first VEGF-targeting drug, which is officially approved in patients with 
metastatic  colorectal  cancer  [13],  metastatic  breast  cancer,  lung  cancer,  renal  cell  carcinomas  and 
glioblastoma multiforme. 
VEGF  expression  is  regulated  by  a  plethora  of  intrinsic  and  extrinsic  factors.  Hypoxia  and 
hypoglycemia  are  major  stimulators  of  VEGF  expression  [14]  (Figure  1).  Hypoxia-induced 
transcription of VEGF mRNA is mediated by the binding of hypoxia-inducible factor 1 (HIF-1) [15]. 
Cytokines may also modulate angiogenesis by regulating VEGF expression. Factors that can potentate 
VEGF production and this way stimulate angiogenesis include e.g. tumor necrosis factor (TNF)-α [16] 
and transforming growth factor (TGF)-β [17]. Intratumoral hypoxia in solid tumors has been found to 
be  a  key  event  in  triggering  angiogenesis  mediated  by  HIF-1  and  one  of  its  downstream  genes,  
VEGF [18]. Tight control of angiogenesis is maintained by a balance of endogenous anti-angiogenic 
and pro-angiogenic factors. VEGF has a key, rate-limiting role in promoting tumor angiogenesis and 
exerts its effects by binding to one of three tyrosine kinase receptors: VEGF receptor-1 (VEGFR-1), 
VEGFR-2 and VEGFR-3. VEGFR-1 (ligands include VEGF-A, -B and placental growth factor [PIGF]) Int. J. Mol. Sci. 2011, 12                       
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and  VEGFR-2  (ligands  include  VEGF-A,  -C  and  -D)  are  predominantly  expressed  on  vascular 
endothelial cells, and activation of VEGFR-2 appears to be both, necessary and sufficient, to mediate 
VEGF-dependent  angiogenesis  and  induction  of  vascular  permeability  [9,19].  VEGF-A  binds  to 
VEGFR-1 and VEGFR-2, whereas VEGF-B as well as PlGF only binds to VEGFR-1. Both receptor 
tyrosine kinases are expressed in all adult endothelial cells except for endothelial cells in the brain. 
VEGFR-1  is  also  expressed  on  hematopoietic  stem  cells  (HSC),  vascular  smooth  muscle  cells, 
monocytes,  and leukemic cells [20,21]. Although the exact contribution of VEGFR-1 signaling to 
angiogenesis  is  unclear,  it  has  been  shown  to  co-operate  directly  with  VEGFR-2  via 
heterodimerization, as well as to bind two additional VEGF homologues, VEGF-B and PIGF [22]. 
VEGFR-3, largely restricted to lymphatic endothelial cells, binds the VEGF homologues VEGF-C and 
VEGF-D and may play an important role in the regulation of lymphangiogenesis.  
Figure 1. Simplified scheme of the interactions between tumor cells, bone-marrow-derived 
cells, and immune  cells with the endothelial system. Hypoxia is a major stimulator of 
VEGF expression. Tumor cells produce VEGF and other pro-angiogenic factors like basic 
fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF) and a variety of 
pro-inflammatory cytokines stimulating endothelial cells to proliferate. Additionally, the 
endothelial cells were stimulated by tumor-associated fibroblasts and bone-marrow-derived 
angiogenic cells (adapted from [23]. VEGF, vascular endothelial growth factor.  
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Further co-receptors of VEGFR are the neuropilins consisting of two genes, neuropilin-1 (NRP1) 
and neuropilin-2 (NRP2) [24,25]. Initially characterized as neuronal receptors, NRPs were also found 
to be expressed in endothelial cells and subsequently were shown to play a role in the development of 
the vascular system. Besides the presence of NRPs on tumor-associated vessels, NRPs were expressed 
by  a  large  variety  of  tumors  like  lung  cancers  [26],  brain  tumors  [27]  colon  cancers  [28],  and 
pancreatic cancers [29]. Targeting of both, VEGF and NRP-1 could be a more promising approach 
than single agent therapy [30]. 
Members of the FGF family are known to be angiogenic activators mediated by interactions of FGF 
and its receptors FGF1R and FGF2R. Several preclinical and clinical studies suggest an involvement Int. J. Mol. Sci. 2011, 12                       
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of FGF signaling in the development of resistance to VEGF targeting agents. Recently new agents 
targeting  the  FGFR  in  combination  with  other  targets  are  under  clinical  evaluation:  Brivanib  
(BMS-582664)  for  example  is  a  novel  receptor  tyrosine  kinase  inhibitor  that  targets  the  key 
angiogenesis receptors VEGFR-2 and FGFR [31]. 
Angiopoietins belong to a family of growth factors that are involved in blood vessel formation 
during pathological angiogenesis. The importance of Angiopoietin signaling has been recognized in 
transgenic mouse models as the genetic ablation of Ang-1, and its primary receptor Tie2 has led to 
early embryonic lethality [32]. Thus Angiopoetin inhibition represents an attractive target: AMG 386 
is a promising peptide-Fc fusion protein that inhibits angiogenesis by binding angiopoietin-1 and-2 and 
blocking interaction with the Tie2 receptor [33].  
Another  target  of  anti-angiogenic  therapies  is  the  activin  receptor-like  kinase  1  (ALK1),  an 
endothelial  cell  restricted  receptor  of  the  TGF-beta  family.  Activation  of  the  ALK1  receptor  by 
different ligands like bone morphogenetic protein (BMP) 9, BMP 10, and TGF-beta led to endothelial 
cell stimulation, proliferation and migration. For ALK1 inhibition, 3 different compounds are currently 
under clinical development and in phase-I evaluation [34]. 
Standard  noninvasive  imaging  techniques  such  as  ultrasonography  (US),  computed  tomography 
(CT) and magnetic resonance imaging (MRI) are used to detect the success of these therapies, defined 
as reduction in tumor size [35]. In contrast to cytotoxic and cytostatic tumor therapies, new biological 
anti-cancer therapies, such as anti-angiogenic attempts, may reach biological activity at lower doses. 
Thus, the development of predictive biomarkers for anti-angiogenic therapies is urgently needed to 
select those patients most likely to derive benefit, to prevent unnecessary toxicity in resistant patients 
and to avoid high therapy costs.  
This review focuses on the current knowledge of biomarkers in angiogenesis and its significance 
during anti-angiogenic therapy. 
2. Tissue Sampling/Tissue Biomarker 
Since high VEGF expression in tumors is known to correlate with advanced clinical stage and 
worse prognosis, VEGF expression levels in tumor tissues have been hypothesized to correlate with 
response and benefit from anti-angiogenic agents. Admittedly first analyses of VEGF expression levels 
in tissue samples of metastatic breast and colorectal cancer patients treated with bevacizumab could 
not verify this hypothesis [36].  
Also  the  evaluation  of  microvessel  density  (MVD)  which  is  known  to  reflect  the  amount  of 
vascularization in tissue was thought to be a potential predictive marker of anti-angiogenic efficacy. 
Although  in  preclinical  models  MVD  proved  to  be  a  predictive  marker,  it  failed  in  clinical  
settings  [37].  There  are  several  possible  explanations  discussed  why  MVD  failed  to  reflect  anti-
angiogenic therapy like tumor heterogenity or intraobserveral bias. 
Many studies attempted to analyze the whole VEGFR signaling cascade by different techniques and 
to correlate alterations with clinical response. For example, immunohistochemical (IHC) analyses of 
naive 21 breast cancers an increased amount of phosphorylated and thus active VEGFR2 (pVEGFR2) 
was observed. After therapy with bevacizumab the amount of pVEGFR2 decreased, a finding that also 
correlated with clinical efficacy [38]. In hepatocellular carcinoma (HCC) the treatment of sorafenib Int. J. Mol. Sci. 2011, 12                       
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was  more  efficacious  in  patients  with  a  highly  active  mitogen  activated  protein  kinase  (MAPK) 
determined by IHC staining of pERK [39]. The results of the validation study (SHARP trial phase III 
comparing  best  supportive  care  versus  sorafenib  in  advanced  HCC)  of  the  MAPK  activity  status 
are awaited.  
Moreover genomic analyses of the mutational status of the VEGFR (KDR) gene in angiosarcoma 
patients  identified  some  mutations  which  correlated  with  increased  sensitivity  to  VEGFR  tyrosine 
kinase inhibitors (TKI)  therapy [40]. These activating mutations occurred in 10% of the analyzed 
patients and correlated further with a strong KDR protein expression. Further evaluation is needed 
regarding EGFR (epidermal growth factor receptor), as TKIs are highly effective in patients harboring 
activating EGFR mutations [41]. 
Also germline genetic alterations in the promoter region showed to be of clinical relevance and are 
considered to be potential predictive markers for efficacy of anti-angiogenic therapies. The VEGF 
gene is highly polymorphic and many single nucleotide polymorphisms (SNPs) are described [42]. 
First  studies  from  metastatic  breast  cancer  evaluated  the  combination  of  chemotherapy  plus 
bevacizumab compared  to chemotherapy alone  analyzing SNPs in the  VEGF  gene [43]: Different 
SNPs  were  found  to  correlate  with  a  prolonged  overall  survival  in  the  combination  arm  of 
chemotherapy plus bevacizumab compared with chemotherapy alone. Further SNPs were characterized 
and were associated with a favorable adverse event profile (less grade 3-4 hypertension). Generally 
hypertension is a specific side effect of anti-angiogenic therapies due to the reduced synthesis of nitric 
oxide (NO) in endothelial cells leading to vasoconstiction. Different studies reported an increased 
response rate for patients developing hypertension during anti-angiogenic therapies. Rini et al. [44] 
showed that patients with metastatic renal cell cancer (RCC) on sunitinib therapy had better response 
rates if they developed hypertension under sunitinib therapy. In addition a retrospective analysis of the 
ECOG  4599  study  evaluating  the  addition  of  bevacicumab  to  standard  chemotherapy  in  NSCLC  
(non-small cell lung cancer) observed that elevated blood pressure levels during bevacizumab therapy 
was  associated  with  improved  therapy  outcomes  [45].  Recently  Maitland  et  al.  published 
recommendations of a cardiovascular toxicity expert panel for an optimized treatment of hypertension 
induced by anti-angiogenic therapies [46]. 
Another important point is that tissue samples allow to evaluate the stromal compartment and the 
tumor microenviroment. Many preclinical studies showed that stromal interactions like myeloid cells 
and fibroblast interactions lead to acquired resistance to anti-angiogenic agents [47]. Cascone et al. [48] 
showed in a mouse model that during anti-angiogenic therapy in the stromal compartment EGFR and 
FGFR (fibroblast growth factor receptor) mediated pathways were upregulated and inhibited efficacy 
of  anti-angiogenic  agents.  Thereafter  combined  inhibition  of  EGFR  and  anti-  VEGF  restored  the 
antitumor effect.  
Also tumor infiltrating myeloid cells showed an impact on efficacy of anti-angiogenic therapies. In 
various preclinical studies myeloid cells caused a stimulation of the angiogenic network independently 
of  the  VEGF  signaling  cascade  consequently  contributing  to  an  acquired  resistance  against  anti-
angiogenic therapies [49]. This subpopulation of myeloid cells (CD11b+Gr1+ cells) can be mobilized 
by G-CSF, IL-6 and SDF1α from the bone marrow [50]. CD11b+Gr1+ cells were further characterized 
by the expression of the Bv8 protein [51]. Bv8 is related to the endocrine gland derived VEGF and was 
first extracted from the skin of a frog [52]. Functional analyses of Bv8 showed to induce mobilization Int. J. Mol. Sci. 2011, 12                       
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of  myeloid  cells  from  the  bone  marrow  and  to  circumvent  VEGF  mediated  angiogenesis  [53]. 
Therefore Bv8 is an attractive target and first inhibition studies of Bv8 in preclinical models with 
neutralizing antibodies proved tumor shrinkage and angiogenesis inhibition [54]. 
In  conclusion,  in  situ  biomarker  evaluation  of  predictive  biomarkers  is  an  important  tool  for 
translational  research  studies,  but  limited  by  the  invasiveness  of  tissue  sampling  and  also  by  the 
heterogeneity of the tumor tissue. 
3. Blood Soluble Markers  
The  evaluation  of  angiogenic  parameters  in  serum/plasma  samples  with  standard  immunogenic 
assays is another attractive method for monitoring anti-angiogenic therapies not only because of its 
feasibility and its low costs.  
However  in  four  different  phase  III  studies  evaluating  bevacizumab  in  combination  with 
chemotherapy (AVF2107g, E4599, AVAiL and AVOREN) baseline VEGF levels were not able to 
predict response to anti-angiogenic therapy [55]. In contrast to these findings, Dowlati et al. showed 
that high VEGF levels at baseline correlated with high response rates to bevacizumab therapy (in 
combination with standard chemotherapy) [56]. 
Briefly, these early biomarker studies showed that angiogenesis is a complex network regulated by 
a variety of cytokines and that the determination of a dynamic marker profile including more than one 
single candidate biomarker could be of relevance. 
Subsequent studies evaluated beside VEGF numerous circulating angiogenic factors (CAFs, up to 
40  angiogenic  and  immunological  markers  at  defined  timepoints).  In  metastatic  colorectal  cancer 
Kopetz  et  al.  [57]  analyzed  a  CAF  panel  during  FOLFIRI  plus  bevacizumab  therapy  and  could 
demonstrate  that  several  measured  cytokines  like  bFGF,  PlGF,  MMP-9  and  HGF  or  PDGF  were 
altered during therapy. The authors observed increased CAFs like before disease progression occurred, 
so that CAF levels of the blood stream predicted resistance to anti-angiogenic therapies.  
Preclinical  models  hypothesized  that  during  VEGF  blockade  other  important  pro-angiogenic 
cytokines  are  upregulated,  thus  the  anti-angiogenic  effect  could  be  restored  by  blockade  of  the 
upregulated  factors.  In  addition,  a  subset  of  factors  associated  with  myeloid  cell  recruitment 
(monocytes)  was  elevated  at  disease  progression  underlying  the  hypothesis  that  immune  cells 
contribute to evasive resistance mechanisms against anti-angiogenic agents. In a similar study NSCLC 
(non-small cell lung cancer) patients were treated with the VEGFR TKI vadentanib monotherapy or 
with a combination of chemotherapy plus vandetanib [58]. At four different timepoints a panel of 35 
CAFs  was  evaluated  showing  an  increase  of  IL8  and  VEGF  during  vandetanib  therapy  and  a 
concurrent decrease of sVEGFR2. This observed increase of VEGF2 and its corresponding decrease of 
sVEGFR2 might be a specific effect of anti-angiogenic therapies, a finding which could be due to 
increased tumor hypoxia causing an increased VEGF production. 
This inverse correlation was observed already in many  preclinical models and the first clinical 
observation was described by Norden-Zfoni et al. 2007 in gastrointestinal stromal tumors treated with 
sunitinib [59]. In summary, currently VEGF and sVEGF2R determination represents one of the best 
available options for predicting anti-angiogenic efficacy. Int. J. Mol. Sci. 2011, 12                       
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Another  small  study  evaluated  CAF  signature,  which  included  HGF  and  IL-12  in  neoadjuvant 
treated NSCLC patients with pazopanib [60]. They found that CAFs were associated with response to 
pazopanib and identified responding patients with 81% accuracy. This was the first study reporting that 
increased levels of IL-12 (master regulator of TH1 immune response) are good predictors for response 
to anti-angiogenic therapies.  
In summary, to date the relevance of soluble biomarkers in the blood is not entirely investigated due 
to the fact that most candidate biomarkers were evaluated retrospectively and prospective validation 
is missing. 
4. EPC 
Circulating endothelial cells (CEC) are generally known to be increased in cancer patients. CECs 
are  endothelial  cells  originating  from  blood  vessel  walls  expressing  the  phenotype  of  mature 
endothelial  cells.  Elevated  CEC  counts  have  been  associated  with  several  diseases  including 
myocardial infarction and transplant reactions. Moreover there is evidence that CECs are increased in 
cancer patients [61,62].  
Recent studies showed that CEC counts vary during anti-angiogenic therapy: In a breast cancer 
model  it  has  been  shown  that  CECs  positively  correlated  with  tumor  invasiveness  and  tumor  
volume [63]. Thus it is speculated that CECs mirror a vascular remodeling due to high VEGF levels 
produced  by  cancer  cells.  Therefore  CECs  possibly  can  be  used  as  marker  for  angiogenesis  and 
consequently for monitoring anti-angiogenic therapies. 
Different clinical trials tent to measure CEC levels during anti-angiogenic therapy and a positive 
correlation  between  decreased  CEC  numbers  and  progression-free  survival  (PFS)  has  been  
observed  [64,65].  Moreover  greater  baseline  levels  of  CECs  have  been  correlated  with  therapy 
response  to  anti-angiogenic  therapy;  however  at  the  time  of  progression  there  was  an  observable 
decrease in CEC amount [66]. Interestingly this CEC decrease at time of disease progression resulted 
in increased VEGF and FGF levels.  
Taken  together,  measuring  CEC  level  before  anti-angiogenic  therapy,  could  be  a  predictive 
biomarker  for  therapy  response.  Moreover  CEC  measurements  during  anti-angiogenic  therapy  are 
possibly able to anticipate resistance of anti-angiogenic agents. 
Similar to CEC also circulating progenitor cells (CEP) are elevated in cancer patients associated 
with  disease  progression  [67].  In  contrast,  CEPs  are  a  cell  population  originating  from  the  bone 
marrow  expressing  stem  cell  defining  markers.  Mechanistically  there  are  several  hints  that  CEPs 
stimulate vascularization triggered by VEGF levels, mobilizing CEPs from the bone marrow so that 
CEPs are key contributors of tumor vascularization. Several studies found elevated CEP counts in 
several cancer entities including lung, breast and brain cancer; in some of these studies high CEP 
levels  were  found  to  correlate  with  poor  prognosis  and  consequently  with  poor  survival  rates. 
Moreover  CEPs  were  found  in  preclinical  and  clinical  studies  to  play  a  possible  role  in  the 
development  of  resistance  mechanisms  against  anti-angiogenic  therapy  and  to  chemotherapeutic  
agents [68]. Thus there is intensive research ongoing to define therapeutic strategies to reduce CEP 
mobilization thereby enhancing on one hand the efficacy of anticancer therapeutics and on the other 
hand to reduce the risk of developing metastases. Int. J. Mol. Sci. 2011, 12                       
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To  summarize,  although  several  studies  observed  relationships  between  CEP  and  tumor  
neo-angiogenesis these findings are still a matter of debate due to the fact that there is no standardly 
defined immunophenotyp and functional characterization of this cell population. Furthermore CEC and 
CEP  in  peripheral  blood  is  rarely  measurable  and  therefore  reproducibility  and  standardization  of 
techniques is difficult.  
5. Imaging Techniques 
5.1. DCE-MRI 
In the absence of predictive biomarkers for antiangiogenic strategies, various imaging techniques 
are  being  examined  as  potential  pharmacodynamic  markers,  including  dynamic  contrast-enhanced 
magnetic resonance imaging (DCE-MRI). Several clinical trials describe a decrease in tumor perfusion 
in  response  to  anti-angiogenic  treatment  [35].  DCE-MRI  is  a  non-invasive  functional  imaging 
technique that permits indirect measurement of tumor hemodynamics [69,70].  It may therefore be 
suitable for monitoring the effects of VEGF signaling inhibitors on tumor vasculature. DCE-MRI, 
using gadolinium chelate as the contrast agent, is a useful technique to study the pathophysiology of 
tumors, particularly with respect to vascular perfusion and permeability. The MRI enhancement is due 
to  increasing  gadolinium  concentration,  largely  in  the  extravascular  and  extracellular  space  and 
depends on tumor perfusion, tumor vascularity and tumor vascular permeability. Gadolinium diffuses 
passively from the blood vessel into the extracellular space at a rate proportional to the concentration 
difference. Once in the extracellular space it disperses freely without binding and will efflux back into 
the  vascular  space  in  a  similar  manner  with  a  similar  rate  constant.  Ki  or  K
trans
  is  an  objective 
measurement quantifying the rate constant for this process. 
DCE-MRI utilizes a low molecular weight paramagnetic contrast agent such as gadolinium-DTPA, 
which readily diffuses from the blood to the extravascular extracellular space. By acquiring a set of 
rapid MR images, the time course of the change in T1 relaxation time induced by the contrast agent 
may be followed. Contrast agent concentration can be calculated from T1 relaxation times using the 
known linear relationship [69]. The time course obtained can be characterized by the initial area under 
the contrast agent concentration-time curve (iAUC) or a pharmacokinetic model may be applied. With 
the latter, the data are fitted to estimate the transfer of contrast agent between the plasma and the 
extracellular,  extravascular  space  (the  transfer  constant  K
trans).  Although  iAUC  and  K
trans  are 
incompletely  validated  endpoints  that  are  sensitive  to  changes  in  a  number  of  hemodynamic 
parameters, including blood flow, blood volume, vessel permeability and vessel surface area [71], 
emerging  data  from  several  early-phase  clinical  trials  of  VEGF  signaling  inhibitors  have  shown 
changes in K
trans and/or iAUC that are consistent with reductions in VEGF-dependent tumor perfusion 
and vascular permeability [72–74]. 
The  method  was  first  described  preclinically  using  vatalanib  (formerly  PTK787/ZK  222584),  a 
specific  inhibitor  of  the  VEGF–receptor  tyrosine  kinases,  which  showed  anti-tumor  and  
anti-angiogenic  activity  in  a  murine  renal  cell  carcinoma  (RENCA)  model.  In  this  model,  after 
intrarenal application of RENCA cells, mice developed a primary tumor and metastases to the lung and 
abdominal lymph nodes [35,75,76]. After daily oral therapy with either vatalanib or vehicle, primary Int. J. Mol. Sci. 2011, 12                       
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tumors of all animals were analyzed by DCE-MRI. Gadolinium-DOTA was used as the contrast agent 
for  detecting  vessel  permeability  and  contrast  agent  extravasation.  Vatalanib  treatment  led  to  a 
significant decrease in vessel permeability. Furthermore, increase in partial blood volume was found in 
the vatalanib-treated group, although vessel density was reduced as seen by histology [75]. Using the 
corrosion  cast  technique,  reduction  in  vessel  density  was  significant  but  not  very  pronounced, 
predominantly due to the loss of microvessels.  
In  the  clinical  phase-I  study,  patients  with  colorectal  cancer  were  treated  with  oral,  once-daily 
vatalanib  at  doses  ranging  from  50  to  2000  mg  day  [69].  In  that  study,  early  changes  in  tumor 
vascularity  and  vascular  permeability  (Ki)  were  assessed  by  DCE-MRI  as  biomarkers  of  clinical 
activity and correlated with vatalanib pharmacokinetics and subsequent clinical outcome after 56 days 
of treatment. A 60% decrease in Ki was significantly correlated with non-progressive disease after two 
cycles of vatalanib treatment. 
In  another  phase-I  study  with  cediranib  (AZD2171,  Recentin®),  a  potent  inhibitor  of  both
  
VEGFR-1  and  VEGFR-2,  DCE-MRI  was  used  to  evaluate  the  anti-angiogenic  activity  of  
cediranib [74]. Patients with solid tumors and liver metastases refractory to standard therapies received 
once  daily  oral  AZD2171  (0.5  to  60  mg).  Altogether  eighty-three  patients  received  cediranib. 
Pharmacodynamic assessments demonstrated time-, dose-, and exposure-related decreases in initial  
area  under  the  curve,  defined  over  60  seconds  post-contrast  arrival  in  the  tissue  (iAUC60)  using 
dynamic  contrast-enhanced  magnetic  resonance  imaging,  as  well  as  dose-  and  time-dependent 
reductions in soluble VEGF receptor 2 levels. The reduction in iAUC60 on day 2 observed in this study 
suggests a reduction in vascular permeability, whereas the sustained effects on days 28 and 56 are 
likely  to  reflect  changes  in  blood  flow.  Overall,  the  findings  from  the  DCE-MRI  investigation 
demonstrated that cediranib modulates tumor vascular physiology and reduces tumor blood flow and 
vascular permeability [74].  
DCE-MRI is a promising biomarker for assessing anti-angiogenic treatment. However, standardized 
methods are required to establish reliable sources in evaluation of antitumor therapy. In contrast to 
previous methods, in which MRI was added as a clinical endpoint, prospective studies are needed to 
test standardized DCE-MRI methods and to establish MRI as a biomarker itself, which can be used in 
very early stages of drug development, to monitor anti-tumor effects and correlate them with existing 
prospective biomarker performance. Quantification by use of pharmacokinetic modeling necessitates 
calibration  to  determine  the  relationship  between  concentration  of  the  contrast  agent  and  signal 
intensity; however, there is no simple relationship between contrast concentration and signal-intensity, 
especially at high contrast concentration [77]. 
5.2. Ultrasound 
Ultrasound is a favored modality for imaging angiogenesis because it does not expose patients to 
any radiation risks, it is widely available, can be repeated often and it is mobile. However, B-Mode 
ultrasound remains limited in imaging angiogenesis because small vessels cannot be detected [35]. 
Knowledge about ultrasound and especially Doppler ultrasound has been dramatically improved in 
recent  years,  mainly  by  software  developments.  Color  Doppler  reveals  the  vascular  anatomy  of 
tumors—even  the  branching  pattern,  shunts  and  blind  ending  vessels  can  be  visualized—and  are Int. J. Mol. Sci. 2011, 12                       
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standardized with visual scoring systems. Early data produced in animal studies indicated that results 
from  Doppler  methods  are  not  correlated  to  the  absolute  micro-vessel  density  because  they  can 
visualize only larger vessels but the measurement of blood flow velocity with color Doppler ultrasound 
can be correlated with effects from anti-angiogenic therapy. 
In  a study  addressing animal models like murine renal  cell carcinoma (RENCA), developing  a 
primary tumor and metastases to the lung and abdominal lymph nodes after intrarenal application of 
tumor cell color Doppler imaging ultrasound was evaluated [76]. Primary tumors were located in all 
animals using a sonograph having a direct-contact high frequency ultrasound transducer. The left renal 
artery was detected by color Doppler imaging, and measurements of systolic and diastolic blood flow 
velocity and resistance index were performed and compared between animals that were treated with an 
anti-angiogenic agent or not. Taking the values from the control vessel (abdominal aorta) into account, 
reduction of systolic blood flow velocity in animals treated with an anti-angiogenic agent could be 
confirmed, showing a reduction in systolic blood flow velocity by 44% [76]. 
In the same RENCA model, ZD6126, a vascular-disrupting agent that affects the endothelial tubulin 
cytoskeleton causing selective occlusion of tumor vasculature and extensive tumor cell necrosis, was 
examined. ZD6126 treatment led to a significant reduction in tumor size and was associated with 
extensive  tumor  necrosis  and  a  reduction  in  tumor  blood  flow  measured  by  Doppler  imaging 
ultrasound technique [78].  
In a clinical study with vatalanib in patients with colorectal cancer treated with oral, once-daily 
vatalanib  was  designed  to  evaluate  contrast-enhanced  color  Doppler  imaging  as  a  biomarker  for  
anti-angiogenic treatment [79]. As inclusion criteria, a tumor vessel in a liver metastasis had to be 
present with a good signal-to-noise ratio. Blood flow measurements were performed at baseline, day 3 
and at day 28 as well as after each additional treatment cycle. The systolic and diastolic blood flow 
was measured in the tumor vessel as well as in the hepatic artery. Heart rate and blood pressure 
measurements  were  measured.  The  resistance  index  (RI)  was  calculated  as  follows:  
RI = (Vsys – Vdia)/Vsys. In contrast to the animal studies, no significant dose-related changes could be 
described for the RI. There was a trend to a higher blood flow with increasing doses of vatalanib but 
the results are not significant due to the very small sample size [79]. 
The  future  role  of  ultrasound  as  well  as  contrast-enhanced  color  Doppler  imaging  in  
anti-angiogenic  agents  will  be  defined  by  addressing  the  challenges  of  examiner-dependent 
reproducibility of results. 
6. Biomarkers under Anti-Angiogenic Therapies 
6.1. Anti-Angiogenic Therapies 
Anti-angiogenic  therapies  are  mostly  based  on  inhibiting  the  binding  of  VEGF  to  VEGFR  by 
neutralizing antibodies to the ligand or to the receptor, soluble receptors, small molecule inhibitors or 
are directed against the tyrosine kinase activity of the VEGF receptors [5] (Figure 2). We will focus on 
several molecules interfering with the VEGF/VEGFR system, which already have been approved or 
are currently evaluated in clinical trials for solid tumors. Int. J. Mol. Sci. 2011, 12                       
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Figure  2.  Therapeutic  strategies  to  target  the  VEGF/VEGF  receptor  system  (adapted  
from [5]). VEGF, vascular endothelial growth factor.  
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6.2. Receptor Tyrosine Kinase Inhibitors 
Small  molecule  VEGF  receptor  tyrosine  kinase  inhibitors  are  a  further  important  class  of  
anti-angiogenic drugs.  
6.3. Sorafenib  
Sorafenib (Nexavar
®) is a multikinase inhibitor of VEGFR2-3, PDGFR, Raf kinase and c-Kit the 
receptor of stem cell factor, currently approved for the treatment of advanced HCC and renal cell 
carcinoma  (RCC)  [5,80].  In  a  phase-II  trial  evaluating  sorafenib  in  previously  treated  advanced 
NSCLC assessed possible predictive biomarkers in 34 evaluable patients [81]. Among them the effect 
of VEGF increase and sVEGFR2 decrease was observed again, further decreased bFGF levels were 
correlated with increased survival and disease progression. Also functional imaging with DCE-MRI 
was performed and Kep showed a significant predictive value for overall and progression-free survival. 
Hypertension is known to be a class specific side effect of anti-angiogenic agents due to inhibited 
NO production in endothelial cells. Maitland and colleagues found that sorafenib administration leads 
to a blood pressure raise within 24 hours [82].  
6.4. Cediranib 
Cediranib (AZD2171; Recentin
®) is a potent inhibitor of both
 VEGFR-1 and VEGFR-2; it also has 
activity  against  c-kit,  PDGFR-β,
 and  FLT4  at  nanomolar  concentrations  [83].  Cediranib  has  been 
shown
 to inhibit VEGF signaling. In a phase-I study, cediranib was well tolerated up to
 45mg/d in 
patients
  with  a  broad  range  of  solid  tumors  [74].  The  most  common  toxicities
  include  diarrhea, 
dysphonia, and hypertension. Pharmacodynamic assessments demonstrated time-, dose-, and exposure-
related decreases in initial area under the curve, defined over 60 seconds post-contrast arrival in the Int. J. Mol. Sci. 2011, 12                       
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tissue (iAUC60) using DCE-MRI, as well as dose- and time-dependent reductions in soluble VEGF 
receptor 2 levels [74]. In a phase-I study with cediranib in 35 patients with acute myeloid leukemia 
(AML),  the  most  common  adverse  events  were  diarrhea,  hypertension  and  fatigue.  Dose  and  
time-dependent reductions in sVEGFR-2 were observed, and there was a positive correlation between 
cediranib  exposure  and  the  change  in  plasma  VEGF  levels  from  baseline  [84].  Blood  pressure 
elevation seems to be a class-specific side effect of most anti-angiogenic agents (sorafenib, sunitinib, 
bevacizumab  and  axitinib)  due  to  the  decreased  production  of  nitric  oxide  and  prostacyclines  in 
vascular endothelial cells. The hypertension can be treated with standard medication. Therefore, blood 
pressure monitoring during anti-angiogenic therapy is recommended [85]. 
In a phase-II study randomized, factorial, double-blind study of cediranib in patients with advanced 
solid  tumors,  the  hypertension  management  was  prospectively  investigated  [85].  All  patients 
developing  hypertension  on  cediranib  treatment  were  treated  with  a  standardized,  predefined 
hypertension  management  protocol.  Antihypertensive  prophylaxis  did  not  result  in  fewer  dose 
reductions or interruptions. Increases in blood pressure, including moderate and severe readings of 
hypertension,  were  seen  early  in  treatment  in  all  groups  and  successfully  managed.  Severe 
hypertension occurred in one patient receiving prophylaxis versus 18 in the nonprophylaxis groups. 
They concluded that early recognition and treatment of hypertension is likely to reduce the number of 
severe hypertension events. This protocol is included in all ongoing cediranib clinical studies. 
6.5. Sunitinib  
Sunitinib  (Sutent
®)  is  a  multikinase  inhibitor  of  VEGFR  1-3,  RET  and  PDGFRα/β,  currently 
approved  for  the  treatment  of  RCC,  imatinib-resistant  gastrointestinal  stromal  tumors  (GIST)  and 
pancreatic neuroendocrine tumors (pNET) [86–88]. 
Many studies on sunitinib included biomarker programs to identify predictive markers for response. 
Perez-Gracia et al. anyalzed a large panel of 174 cytokines before and after treatment with sunitinib 
and found that baseline TNF-alfa and MMP-9 levels were predictive for sunitinib activity [89]. In 
contrast, Farace et al. found no correlation between CAFs and response to sunitinib therapy, but they 
described an increase of CEP as marker for therapy response [90]. Another study evaluated a panel of 
16 biomarkers involved in tumor pathways targeted by sunitinib, using real-time quantitative reverse-
transcriptase PCR in patients with metastatic RCC [91]. Only the levels of VEGF soluble isoforms 
(VEGF121  and  VEGF165)  were  associated  with  response  to  sunitinib  therapy  and  the  ratio  of 
VEGF121/VEGF165 was a strong prognostic marker. 
Biomarker analyses of HCC patients treated with sunitinib showed a correlation between decreased 
levels of IL-6 and soluble c-KIT and a delayed tumor progression; vice versa elevated levels of IL-6 
and c-KIT were associated with an unfavorable disease course [92]. In this study no correlation of 
VEGF cytokines (like VEGF, sVEGFR) and therapy response was observed. However, responders to 
sunitinib therapy could be detected by a decrease of the vascular permeability measured by DCE-MRI, 
which was correlated with a delayed progression.  Int. J. Mol. Sci. 2011, 12                       
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6.6. Anti-VEGF Monoclonal Antibodies 
Bevacizumab  
Bevacizumab  (Avastin
®)  is  a  humanized  monoclonal  antibody  IgG1  which  was  created  from  a 
murine  anti-human  VEGF  monoclonal  antibody  that  blocks  the  binding  of  human  VEGF  to  its 
receptors, thereby disrupting autocrine and paracrine survival mechanisms mediated by VEGFR-1 and 
VEGFR-2 [93]. Bevacizumab is the first VEGF targeting drug, which has been officially approved for 
cancer therapy. Bevacizumab demonstrated survival benefits in patients with metastatic colon cancer 
when combined with conventional chemotherapy [13]. Since then, it has been tested in several other 
cancer types.  
The determination of the optimal biological dose of bevacizumab for clinical use was challenging 
and not conclusive, as shown by the various doses of bevacizumab used in phase III trials [94,95]. 
Inhibition  of  VEGF  signaling  may  induce  a  hypertensive  response.  Bevacizumab  inhibits  VEGF 
signaling to endothelial cells, which leads to rapid rises in blood pressure [96]. Hypertension, therefore, 
could  be  a  useful  surrogate  marker  of  VEGF  activity  and  predict  the  anti-angiogenic  activity  of 
bevacizumab [96]. 
In a recent study, hypertension was examined as biomarker in patients with metastatic colorectal 
cancer  treated  with  chemotherapy  and  bevacizumab  [97].  Overall,  57  patients  (56%)  developed  ≥ 
grade  1  hypertension  (median  blood  pressure  168/97  mm  Hg),  whereas  44  (44%)  remained 
normotensive  when  treated  with  bevacizumab-containing  chemotherapy  regimen.  Overall  response 
rate  was  higher  among  patients  with  hypertension  (30  vs.  20%;  p  =  0.025).  Hypertension  was 
associated  with  improved  progression-free  survival  (10.5  vs.  5.3  months;  p  =  0.008)  and  overall 
survival (25.8 vs. 11.7 months; p < 0.001) and development of hypertension within 3 months had an 
independent,  prognostic  influence  in  a  multivariate  landmark  survival  analysis  together  with  other 
known colorectal cancer prognostic factors (p = 0.007).  
In  a  phase-III  study  of  bevacizumab  in  combination  with  interferon  alfa  versus  interferon  alfa 
montherapy in patients with metastastic renal cell carcinoma, patients in the combination arm had 
significantly  more  grade  3  to  4  hypertension  [98].  Patients  who  developed  hypertension  on 
bevacizumab plus interferon alfa had a significantly improved progression-free survival and overall 
survival versus patients without hypertension. Contrary, an analysis of 5,900 patients across 6 phase-
III studies of metastatic cancer treated with bevacizumab was performed by Hurwitz et al. [99]. In 5 of 
6  studies,  hypertension  during  bevacizumab  treatment  was  not  predictive  of  clinical  benefit  or 
prognostic for the course of disease. 
Soluble plasma and serum markers of angiogenesis and of activated endothelial cells can also be 
used  to  assess  anti-angiogenic  activity  [100].  VEGF  levels  can  be  predictive  of  responding  to  
anti-angiogenic therapy [79,80]. 
In a recent study, molecular and genetic markers to predict or monitor the efficacy of bevacizumab 
was  investigated  in  patients  of  metastatic  colorectal  cancer  [101].  Plasma  levels  of  VEGF,  PlGF, 
sVEGFR-2 and thrombospondin-1 were assessed by ELISA assay at different time points in a cohort 
of 25 patients enrolled in a phase-II trial. Treatment with FOLFOXIRI plus bevacizumab determined a 
prolonged  and  significant  reduction  in  plasma  free,  biologically  active  VEGF  concentration. Int. J. Mol. Sci. 2011, 12                       
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Interestingly,  VEGF  concentrations  remained  lower  than  at  baseline  also  at  the  time  of  
progressive disease. 
In  a  phase-II/phase-III  trial,  patients  with  advanced  NSCLC  were  randomized  to  carboplatin  + 
paclitaxel (PC arm) or  PC + bevacizumab (BPC arm) [56]. VEGF, basic fibroblast  growth factor 
(bFGF), soluble intercellular adhesion molecule (ICAM) and E-selectin was measured pretreatment 
and during therapy. Baseline ICAM showed significant associations with response and survival in both 
groups. Patients with low baseline ICAM had a higher response rate (32% vs. 14%; p=0.02), better 
overall survival (p = 0.00005), and better 1-year survival (65% vs. 25%) than those with high ICAM, 
respectively, regardless of treatment arm. Patients with high VEGF levels were more likely to respond 
to BPC compared with PC, but this was not predictive of survival. The results also suggest a benefit 
from bevacizumab for patients with low baseline ICAM levels (53% reduction in the progression-free 
survival hazard rate). 
In a recent study, predictive biomarkers were investigated in patients with metastatic breast cancer 
treated  with  bevacizumab  and  capecitabine  [55].  Biomarker  expression  was  assessed  by  in  situ 
hybridization (VEGF-A, VEGF-B, thrombospondin-2 and Flt4) or immunohistochemistry (VEGF-C, 
PDGF-C,  neuropilin-1,  delta-like  ligand  (Dll)  4,  Bv8,  p53  and  thymidine  phosphorylase)  on  
formalin-fixed, paraffin-embedded tissue. Patients with low scores for Dll4, VEGF-C, and neuropilin-1 
showed  trends  toward  improvement  in  progression-free  survival  associated  with  the  addition  of 
bevacizumab to capecitabine. 
Regarding DCE-MRI to measure non-invasive efficacy of bevacizumab therapy in cancer patients, 
a phase-II trial examined the additional biomarker effect on angiogenesis when bevacizumab is added 
to docetaxel in patients with inoperable breast cancer [102]. Plasma and serum markers of endothelial 
damage, DCE-MRI, and tumor microvessel density were assessed before treatment and at the end of 
each cycle. VEGF increased during treatment; more so with docetaxel-bevacizumab than docetaxel 
alone (p < 0.0001). DCE-MRI showed a greater decrease in tumor perfusion calculated by initial area 
under the curve for the first 90 seconds in docetaxel-bevacizumab than docetaxel alone (p = 0.024). 
DCE-MRI also showed an overall decrease in tumor volume (p = 0.012). 
7. Conclusions 
Angiogenesis is essential in the development of malignancies. In such instances, VEGF/VEGFR-
related pathways are the most relevant regulators of neoangiogenesis, vasculogenesis, and recruitment 
of endothelial progenitor cells. Furthermore, VEGF/VEGFR interactions can stimulate proliferation, 
migration,  and  survival  of  tumor  cells.  Anti-angiogenic  therapies  are  integrated  in  the  treatment 
management of many different tumor entities. However, not all patients respond to therapy and only a 
few benefit by progression-free survival. Thus, it is important to find predictive biological markers of 
objective response, as the response rate correlates with overall survival, or involved in resistance to 
anti-angiogenic drugs in order to improve therapy efficacy, or to propose alternative anti-angiogenic 
therapy in case of treatment failure. Most of the promising soluble, tissue and imaging biomarkers will 
need to be validated in prospective trials as currently no “ideal” biomarkers exist which identifies 
patients most likely to receive the greatest benefit from anti-angiogenic therapy. 
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